Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advertising regs protect Amylin's Byetta from being maligned, judge says in lifting temporary restraining order against Lilly.
You may also be interested in...
Lilly Diabetes R&D Center Arms Firm For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.
New Diabetes R&D Center Arms Eli Lilly For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.